Patents by Inventor Colin P. Dinney

Colin P. Dinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDKN2A COMPANION DIAGNOSTIC FOR BLADDER CANCER INTERFERON THERAPY
    Publication number: 20230310566
    Abstract: A method of treating bladder cancer comprising diagnosing bladder cancer in a human, measuring the human’s level of CDKN2A expression, and then instilling into the human an agent which induces interferon expression.
    Type: Application
    Filed: October 13, 2022
    Publication date: October 5, 2023
    Inventor: Colin P. Dinney
  • CDKN2a Companion Diagnostic for Bladder Cancer Interferon Therapy
    Publication number: 20200360499
    Abstract: A method of treating a human with bladder cancer that is not responsive to treatment with bacillus Calmette-Guérin, comprising measuring the human's level of CDKN2A expression, and then instilling into the human an agent which induces interferon expression, e.g., interferon polypeptide or a gene therapy vector carrying an interferon transgene.
    Type: Application
    Filed: December 11, 2018
    Publication date: November 19, 2020
    Applicant: Trizell Limited
    Inventor: Colin P. DINNEY
  • Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer
    Patent number: 9551713
    Abstract: Methods for predicting cancer recurrence following a BCG immunotherapy are provided. In some aspects, cytokine levels from a patient are measured before and after a BCG therapy and the changes in cytokine levels are used to determine the risk of cancer lapse. Methods for selecting a patient for a further anti-cancer therapy are also provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: January 24, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ashish M. Kamat, Joseph Briggman, Colin P. Dinney, Diana Urbauer
  • USE OF A PANEL OF URINARY CYTOKINES TO PREDICT RESPONSE TO BCG THERAPY FOR BLADDER CANCER
    Publication number: 20150212090
    Abstract: Methods for predicting cancer recurrence following a BCG immunotherapy are provided. In some aspects, cytokine levels from a patient are measured before and after a BCG therapy and the changes in cytokine levels are used to determine the risk of cancer lapse. Methods for selecting a patient for a further anti-cancer therapy are also provided.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 30, 2015
    Applicant: Board of Regents, The University of Texas System
    Inventors: Ashish M. Kamat, Joseph Briggman, Colin P. Dinney, Diana Urbauer
  • Methods and compositions for anti-EGFR treatment
    Patent number: 8841273
    Abstract: In some embodiments, the present invention provides methods for enhancing the sensitivity of cancer cells to anti-EGFR treatment, wherein the method comprises the introduction of a miR-200 miRNA to the cancer cells. In other embodiments, the present invention provides methods for treating cancer by exposing the cancer cells to an anti-EGFR composition after the above-mentioned enhancement step. In other embodiments, the present invention provides methods for assessing and enhancing the sensitivity of cancer cells to anti-EGFR treatment. In various other embodiments, the present invention provides compositions and expression vectors for practicing the afore-mentioned methods.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: September 23, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Liana Adam, Colin P. Dinney, David J. McConkey
  • EPITHELIAL BIOMARKERS FOR CANCER PROGNOSIS
    Publication number: 20130058925
    Abstract: Methods, systems and compositions for the prognosis and classification of cancer, especially bladder cancer, are provided. For example, in certain aspects methods for cancer prognosis using expression analysis of selected biomarkers such as miR-200 and TGFalpha are described.
    Type: Application
    Filed: February 25, 2011
    Publication date: March 7, 2013
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Colin P. Dinney, Alexandru George Floares, Liana Adam
  • METHODS AND COMPOSITIONS FOR ANTI-EGFR TREATMENT
    Publication number: 20130018088
    Abstract: In some embodiments, the present invention provides methods for enhancing the sensitivity of cancer cells to anti-EGFR treatment, wherein the method comprises the introduction of a miR-200 miRNA to the cancer cells. In other embodiments, the present invention provides methods for treating cancer by exposing the cancer cells to an anti-EGFR composition after the above-mentioned enhancement step. In other embodiments, the present invention provides methods for assessing and enhancing the sensitivity of cancer cells to anti-EGFR treatment. In various other embodiments, the present invention provides compositions and expression vectors for practicing the afore-mentioned methods.
    Type: Application
    Filed: October 28, 2010
    Publication date: January 17, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Liana Adam, Colin P. Dinney, David J. McConkey